A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson's disease

Biomarkers. 2016;21(2):129-37. doi: 10.3109/1354750X.2015.1118544. Epub 2015 Dec 3.

Abstract

Context: Sensitive, non-invasive biomarkers that facilitate Parkinson's disease (PD) detection and stage assignment are currently unavailable.

Objective: The objective of this study is to investigate the potential of circulating microRNAs (miRNAs) as novel biomarkers for PD.

Materials and methods: Solexa sequencing technology and quantitative real-time PCR were applied to screen and verify altered serum miRNAs in PD patients.

Results: Serum miR-141, miR-214, miR-146b-5p, and miR-193a-3p were decreased significantly in PD patients compared with controls. Furthermore, the 4-miRNA panel enabled the differentiation of HY stage 1 and 2 PD patients from controls.

Discussion and conclusion: The four serum miRNAs may represent novel biomarkers for the early detection of PD.

Keywords: Biomarker; Parkinson’s disease; RT-qPCR; serum microRNA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood*
  • Early Diagnosis*
  • Female
  • Gene Expression
  • High-Throughput Nucleotide Sequencing / methods
  • Humans
  • Male
  • MicroRNAs / blood*
  • MicroRNAs / genetics
  • Middle Aged
  • Parkinson Disease / blood*
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / genetics
  • Prognosis
  • ROC Curve
  • Reverse Transcriptase Polymerase Chain Reaction
  • Severity of Illness Index

Substances

  • Biomarkers
  • MIRN141 microRNA, human
  • MIRN146 microRNA, human
  • MIRN193 microRNA, human
  • MIRN214 microRNA, human
  • MicroRNAs